Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $60M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 09.05.2022 | E&Inve... | eninvestme... |
| 17.08.2023 | Hercules C... | htgc.com |
| 17.02.2022 | RA Capital... | racap.com |
| - | Adjuvant C... | adjuvantca... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 11.02.2022 | Series A | $60M | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 11.02.2022 | Curevo Vaccine Raises $60M in Series A Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $60M in Series A funding. ... | finsmes.co... |
| 11.02.2022 | Vaccine startup Curevo takes on pharma giant GSK, raises $60... | Curevo CEO George Simeon. (Curevo Photo) Curevo has raised $60 million to develop a new vaccine for... | geekwire.c... |
| 11.02.2022 | Green Cross : Curevo Announces $60 Million Series A Financin... | Curevo's lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has demonstrated... | marketscre... |
| - | Curevo | “https://videos.files.wordpress.com/1c7Vju9e/labsmall.mp4 Creating Next Generation Vaccines for Dise... | fastfounde... |